The DEA's proposed rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, following HHS's 2023 scientific recommendation and a May 2024 notice-and-comment period that drew over 42,000 public inputs, remains stalled without a final rule as of early April 2026. President Trump's December 18, 2025, executive order directed Attorney General Pam Bondi to expedite the process, yet 104 days later, Rep. Steve Cohen's March 27 letter to Bondi and DEA Administrator Cole highlighted key delays: no administrative law judge seated for the required hearing on Docket 24-44, a missed January deadline under the HALT Fentanyl Act, and a Congressional Research Service shift to more cautious language on DEA action. Traders monitor for Federal Register publication amid administration frustration and potential procedural advances.
Experimental AI-generated summary referencing Polymarket data · Updated$285,240 Vol.

June 30
30%

December 31
43%
$285,240 Vol.

June 30
30%

December 31
43%
The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Market Opened: Feb 7, 2026, 5:04 PM ET
Resolver
0x65070BE91...The primary resolution source for this market will be official information from the US government, however a consensus of credible reporting will also be used.
Resolver
0x65070BE91...The DEA's proposed rescheduling of marijuana from Schedule I to Schedule III under the Controlled Substances Act, following HHS's 2023 scientific recommendation and a May 2024 notice-and-comment period that drew over 42,000 public inputs, remains stalled without a final rule as of early April 2026. President Trump's December 18, 2025, executive order directed Attorney General Pam Bondi to expedite the process, yet 104 days later, Rep. Steve Cohen's March 27 letter to Bondi and DEA Administrator Cole highlighted key delays: no administrative law judge seated for the required hearing on Docket 24-44, a missed January deadline under the HALT Fentanyl Act, and a Congressional Research Service shift to more cautious language on DEA action. Traders monitor for Federal Register publication amid administration frustration and potential procedural advances.
Experimental AI-generated summary referencing Polymarket data · Updated


Beware of external links.
Beware of external links.
Frequently Asked Questions